Smallhold, Inc.
In its recent decision in Purdue Pharma, the Supreme Court held that the Bankruptcy Code does not authorize bankruptcy courts to confirm a plan of reorganization that provides for the release of a creditor‘s claim against a non-debtor.1 That holding, however, was expressly limited to nonconsensual third-party releases. The Court made clear that “[n]othing in what we have said should be construed to call into question consensual third-party releases offered in connection with a bankruptcy reorganization plan[.]”2
The law in this jurisdiction before Purdue Pharma permitted nonconsensual third-party releases in exceptional cases.3 But at least in this Court, such cases truly were exceptional.4 Consensual releases, on the other hand, are commonplace. The
The undersigned judge had previously approved of “opt out” third-party releases.7 But the reason this Court reached that conclusion can be described as a “default” theory. Under Continental, whether a nonconsensual third-party release could or could not be imposed on an objecting creditor depended on the evidence the debtor brought forward at the confirmation hearing. The possibility that a plan might be confirmed that provided a nonconsensual release was sufficient to impose on the creditor the duty to speak up if it objected to what the debtor was proposing. In this sense, the third-party release was a contestable plan provision like any other –
This Court thus viewed the practice of providing a ballot with a box affording the creditor the opportunity to “opt out” to be a matter of administrative convenience. In the absence of this kind of ballot, such a creditor could be required to file an objection to the plan on the ground that the high standard established by Continental for nonconsensual third-party releases was not met, and that the plan was therefore unconfirmable. If the creditor filed such an objection, the debtor would carve that creditor out of the third-party release, which would then be enforceable only against those creditors who did not raise an objection – those who “consented” to it. The practice of including a box on creditors’ ballots to check if they objected to the release was just an administrative shortcut to relieve those creditors of the burden of having to file a formal plan objection.
But that analysis is no longer viable after Purdue Pharma. Under established principles, courts in civil litigation will enter default judgments against defendants only after satisfying themselves that the relief the plaintiff seeks is relief that is at
After Purdue Pharma, a third-party release is no longer an ordinary plan provision that can properly be entered by “default” in the absence of an objection. It is unlike the listed cure amount where one can properly impose on a creditor the duty to object, and in the absence of such an objection bind the creditor to the judgment. The nonconsensual third-party release is now per se unlawful. As such, it is not the kind of provision that would be imposed on a creditor on account of that creditor‘s default.
And in the absence of the default theory of “consent,” no other justification for treating the failure to “opt out” as “consent” to the release can withstand analytic scrutiny. Some of the decisions that have authorized the opt-out approach but have not relied on the “default” principle have instead suggested that a creditor‘s consent can be inferred from the fact that the creditor received clear and conspicuous notice of the release and was given the opportunity to opt out of it. But aside from a context in which a default may properly be entered, there is no other context in which that kind of consent provides a lawful basis for separating someone from their own legal rights. That theory of consent simply proves too much. It would authorize courts to impose on creditors “consensual” obligations to which no court would subject a party in the absence of an affirmative expression of consent. Before such an obligation may
Imagine that Party A, after hitting Party B‘s car in the parking garage, wrote a letter to Party B, stating that unless Party B responded to the letter in 10 days, Party B would be obligated to release any claim she might have against Party A in exchange for a payment of $100. No court would treat Party B‘s failure to respond as “consent” to those terms in a way that bound Party B to release her claim against Party A. Treating the failure to check a box on a ballot in bankruptcy is no different. Consider, for example, a plan of reorganization that provided that each creditor who failed to check an “opt out” box on a ballot was required to make a $100 contribution to the college education fund for the children of the CEO of the debtor.8 Just as in the case of Party A‘s letter to Party B, no court would find that in these circumstances, a creditor that never returned a ballot could properly be subject to a legally enforceable obligation to make the $100 contribution. But none of the cases that authorizes the opt-out third-party release provides any limiting principle that would distinguish the third-party release from the college education fund plan. And after Purdue Pharma, there is none.
The plan now before the Court involves some interesting wrinkles. It does not purport to impose a release on a creditor who received a ballot and failed to return it. There are only two categories of creditors who would be bound. First are creditors
The second category of creditors that are deemed to grant the release are those who voted in favor of or against the plan and did not opt out. These creditors were clearly and conspicuously informed that voting on the plan (whether the creditor voted to accept or reject it) would constitute a release unless the creditor opted out. These creditors were provided a simple opt-out tool on the ballot. The Court is satisfied that under these circumstances, the affirmative act of voting, coupled with clear and conspicuous disclosure and instructions about the consequences of the vote and a simple mechanism for opting out, is a sufficient expression of consent to bind the creditor to the release under ordinary contract principles. So these third-party releases, unlike those that the plan purports to impose on creditors who were paid in full and thus did not vote and never made any affirmative expression of consent, may properly be enforced.
This Court is sympathetic to the policy argument in favor of the broader form of opt-out releases. They help achieve the objective of finality and closure, which is an important bankruptcy value. But one could say the same thing about the nonconsensual third-party release as applied to the rare case in which it is critical to
Even so, it bears note that the sky is not falling. There are important ways in which the bankruptcy policies in favor of finality can still be achieved after Purdue Pharma. That decision does not affect the practice of exculpation of estate fiduciaries (which is expressly authorized by Third Circuit precedent) or prevent a debtor in appropriate circumstances from releasing estate causes of action, which under Third Circuit law would eliminate veil-piercing liability.9 The narrower form of opt-out plan, like the debtor provided here for general unsecured creditors, is also permissible. And this Court does not foreclose the possibility (offered in a recent article) that a different outcome on the opt-out question might be appropriate in a case in which the plan process itself builds in the protections of
Smallhold is a Brooklyn, New York-based specialty mushroom farming company.10 Using patented technology, Smallhold‘s indoor mushroom farms produce ecologically sustainable organically grown mushrooms in specialty varieties. The company‘s founders started the business in 2017 with, according to the first-day declaration, “a mission to provide an ecologically sustainable product while building direct connections with mycophiles, artists, farmers, ranchers, and others looking to celebrate fungi, build soil fertility, and grow their own food and plants.”11 Its products, including a mushroom pesto, are available in over 500 locations across ten states.12 The debtor‘s founders sold their shares to Monomyth, which had been a minority investor, in February 2024.13
Smallhold filed for bankruptcy, under subchapter V of chapter 11, later that month. The debtor concluded that it had grown its operations (which included mushroom farms in Brooklyn, New York; Austin, Texas; and Los Angeles, California) faster than customer demand would support. Over the course of its bankruptcy case, the debtor rejected several leases and closed a number of its farms.14 Monomyth
Accordingly, the only contested issue at the August 22, 2024 confirmation hearing was the question of the plan‘s third-party releases. To that end, at the time the debtor filed its amended plan on June 3, 2024 (more than three weeks before the Supreme Court‘s Purdue Pharma decision), the debtor filed a certificate of counsel, which represented that the debtor, “in consultation with the Office of the United States Trustee ... [has] prepared a proposed form of order [governing the plan solicitation process].”16 The certificate of counsel expressly stated that the Office of the U.S. Trustee did not object to the debtor‘s proposed solicitation order.17
The proposed order also contained forms of ballot for creditors in each of the two classes. The ballots to be sent to creditors in Class 1 (a class that included only one creditor — the DIP lender) indicated that “[p]ursuant to the Plan, if you return a Ballot and vote to ACCEPT the Plan, you are automatically deemed to have accepted
Based on the representation in the certificate of counsel that the solicitation procedures were fully consensual, the Court entered the order in the form proposed.23 Between the time that order was entered and the confirmation hearing, the Supreme Court issued its decision in Purdue Pharma, which held that the Bankruptcy Code does not authorize bankruptcy courts to confirm plans that provide for nonconsensual third-party releases. On August 14, 2024 (approximately six weeks after the Supreme Court decision in Purdue Pharma), the U.S. Trustee objected to confirmation of the plan on the ground that it provides for third-party releases based on the opt-out mechanic approved in the solicitation order, which is to say that
The confirmation hearing took place on August 22, 2024. At the hearing, the U.S. Trustee raised two issues. First, the U.S. Trustee argued that the opt-out mechanism was improper, because the granting of a third-party release should require the releasing party affirmatively to express its consent to the release.25 Second, with respect to class 1, the U.S. Trustee argued that it is improper to provide that a creditor that votes in favor of a plan should automatically be deemed to consent to the third-party release.26
Factually, there are two categories of creditors as to whom the validity of their releases are at issue.
- There are the creditors whose claims would be paid in full and equity holders who were unimpaired and thus presumed to accept. Neither of these groups were provided a ballot; and
- Those creditors in class 2 (general unsecured creditors) who voted in favor of or against the plan but did not check the box indicating that they intended to opt-out of the third-party release.
The record is perhaps more ambiguous about a third category – the DIP lender in class 1. The record indicates that the DIP lender, as the only creditor in class 1,
It also bears note that as to the class of general unsecured creditors (class 2) what the debtor proposes is much more modest than the paradigmatic question posed by a typical “opt-out” plan – treating a creditor whose claim is impaired under the plan as “consenting” to the release when that creditor may have simply thrown away its ballot. Here, the debtor does not propose to treat unsecured creditors who did not vote as granting the release. Rather, in the class of unsecured creditors (class 2), the release applies only to those creditors who voted in favor of or against the plan but did not check the box to opt out of the release. The release would also apply, however, to equity holders (who are unimpaired, in this subchapter V case, on account of the
At the confirmation hearing, after the evidence was submitted and the Court heard argument, the Court asked the parties whether it might be possible to enter an order that confirmed the plan (thus allowing the debtor to emerge from bankruptcy) while reserving the question of the third-party release.28 Both the debtor and the U.S. Trustee agreed that doing so would be permissible and appropriate.29 The debtor thereafter filed a certificate of counsel indicating that the parties had agreed to a form of order that so provided.30 The Court entered that form of confirmation order, which provided that the Court would separately address the effectiveness of the third-party releases set forth in § 6.10 of the Plan.31 This Memorandum Opinion is intended to address those remaining issues.
Jurisdiction
The issue now before the Court is one that arises under the Bankruptcy Code and is therefore within the district court‘s “arising under” jurisdiction pursuant to
Analysis
I. The U.S. Trustee‘s objection to the release deemed granted by unimpaired creditors and equity holders and class 2 creditors is properly preserved and presented; the objection to the form of ballot provided to class 1 creditors is not.
The U.S. Trustee objects to three categories of third-party releases provided for in the debtor‘s plan: (1) the releases deemed granted by unimpaired creditors and equity holders; (2) the releases deemed granted by class 2 creditors who did not “opt out“; and (3) the release deemed granted by class 1 creditors (the only one of which appears to be the DIP lender), who would have been deemed to grant the release on account of voting for the plan, without being given the opportunity to opt out.
The first question that ought to be considered is whether the U.S. Trustee should be permitted to object to the opt out mechanism provided for here (as to any of these three categories) after it had expressly consented to the entry of the solicitation order that set forth that mechanism. An argument can certainly be made that the solicitation order, while an interlocutory order, should remain binding under the “law of the case” doctrine.
In engaging that question, there is one point that the Court should clarify at the outset. There are certainly occasions when parties object to release language at the stage of a bankruptcy case when a debtor seeks approval of a disclosure statement and solicitation procedures, and courts overrule those objections on the ground that those are matters that are more appropriately raised as confirmation issues. In
That means that in circumstances in which a release is obviously overbroad or unjustified, a court could take up the issue at the disclosure statement stage. But (particularly before Purdue Pharma) if a Court believed that it was possible that the evidence introduced at the confirmation hearing might inform the question of the release‘s propriety, a court could also defer consideration of the issue until confirmation.
In this Court‘s view, however, the substance of the release is different from the procedure the debtor proposes to use to solicit creditors. The reason debtors file motions for courts to approve their solicitation procedures is so that, before the estate incurs the expense of distributing the disclosure statement and plan ballot to creditors, all parties in interest have a chance to weigh in on the propriety of the proposed procedures, and the Court can resolve any dispute about them. Once a court has considered the motion and decided that the procedures are appropriate, that decision should not generally be subject to a subsequent challenge. That is the work
That is not to say that a court could not, after approving solicitation procedures, decline to confirm a plan on the ground that the procedures were improper. A solicitation order, which is entered as an intermediate step in the plan confirmation process, is an interlocutory one. And courts always have the authority to reconsider their interlocutory orders if circumstances warrant such reconsideration.34 But the point of the law-of-the-case doctrine is that unless there is a reason to do so, things that have been decided should not later be undecided.
The law has long recognized an exception to that doctrine, as applied to interlocutory rulings, in circumstances in which “controlling authority has since made a contrary decision of law applicable to such issues.”35 And at least as applied to the class 2 creditors and those creditors and equity holders who were never provided a ballot, the Court is satisfied that the Purdue Pharma decision is sufficient subsequent “controlling authority” to warrant reconsideration of the solicitation order. In view of this Court‘s Arsenal decision, there would not have been much point to objecting to the solicitation procedures on the ground that they permitted opt-out
The Court has a different reaction, however, to the U.S. Trustee‘s complaint about the form of ballot provided to class 1 creditors. The argument the U.S. Trustee makes there is that it is improperly coercive to require a creditor, in order to be permitted to vote in favor of a plan, to grant a third-party release. The Court views that argument as a serious one. In addition to (and perhaps more problematic than) the issue of “coercion” is the concern that such a practice discourages creditors from voting and may distort the voting process, which is intended to provide a valuable signal about the extent of creditor support, within each voting class, for the plan‘s treatment of creditors’ allowed claims. None of those points, however, has been materially changed by the Purdue Pharma decision. And the issue may well be beside the point here, where the only creditor that received this form of ballot was the DIP lender, which has participated actively in the bankruptcy case and expressly negotiated a form of appropriate release. But to the extent the U.S. Trustee would otherwise be permitted to challenge the plan on the basis of the treatment of the release being given by the DIP lender, its failure to raise this issue in connection with the solicitation motion bars it from raising the same issue now.
II. After Purdue Pharma, a creditor granting a third-party release typically must affirmatively evidence its consent to the release.
On the central question presented, the Court concludes that its decision in Arsenal does not survive Purdue Pharma. The rationale of Arsenal was that creditors
Applying these principles to this case, the unimpaired equity holders and creditors whose claims will be paid in full and thus were not given the opportunity to vote cannot be said to have consented to the releases. Purdue Pharma left open the question whether in an appropriate case a nonconsensual release may be imposed on creditors whose claims are satisfied in full under a plan. On the undeveloped record here, however, the Court will not engage that question in this case. These parties therefore cannot be said to have granted a release.
The class 2 creditors who voted on the plan (whether they voted for or against), however, have taken a sufficient affirmative step to be deemed to consent to the third-party releases. These creditors were clearly informed and on notice of the right to opt-out of the releases before casting their votes. And because the ballot provided a simple mechanism by which these creditors could opt out, there is no risk of coercion
A. As a general proposition, creditors must affirmatively express consent to the release in order to be bound by it.
The question of a bankruptcy court‘s authority to grant a nonconsensual third-party release is one on which courts were divided for many years before the Supreme Court‘s recent decision in Purdue Pharma. The Court is not aware, however, of any court that has found that a creditor cannot consensually release a claim against a third-party under a debtor‘s plan of reorganization. And in holding that bankruptcy courts may not grant a nonconsensual third-party release, the Supreme Court‘s decision in Purdue Pharma went out of it its way to emphasize that “[n]othing in what we have said should be construed to call into question consensual third-party releases offered in connection with a bankruptcy reorganization plan[.]”36
That statement, however, raises a different question, and one that has also divided bankruptcy courts – what counts as consent for the purposes of a consensual
This Court addressed that question in Arsenal. There, the Court concluded that it was satisfied that the opt-out mechanism was appropriate. The premise of that conclusion, however, was called into question by Purdue Pharma and is thus appropriately reconsidered.
In Arsenal, the Court broadly characterized the then-existing caselaw as falling within one of two categories. One category of cases emphasized that the rights that a creditor holds against a third party are the creditor‘s property. Outside of bankruptcy, one generally cannot infer that a party has “consented” to an arrangement whereby the party will give up its property based on the party‘s silence. As Judge Bernstein explained in SunEdison, a party seeking to enter into a contract with another “cannot ordinarily force the other party into a contract by saying, ‘If I do not hear from you by next Tuesday, I shall assume you accept.‘”37
Does that mean that the Court expects that each contractual counterparty has opened the mail, found its agreement on the schedule, and determined that the listed cure amount is in fact correct? Of course not. As the Court noted in Emerge Energy Services, it is just as likely (or perhaps more likely) that any particular counterparty‘s failure to respond was a result of “[c]arelessness, inattentiveness, or mistake.”38 But in the context of the sale of the debtor‘s business, courts routinely conclude that creditors and other parties in interest who are validly served with motions and other
This Court‘s reasoning in Arsenal, in which it concluded that the opt-out mechanism was generally permissible, relied on this rationale, which had been expressed by the bankruptcy courts in cases such as DBSD, Indianapolis Downs, Mallinckrodt, and Boy Scouts.39 In this Court‘s view, under then-controlling law, a third-party release was just a provision contained in a plan of reorganization, not fundamentally different from any other. And the Court explained that a party that objected to such a provision was required to speak up by objecting to the inclusion of that provision, much like the contractual counterparty must if it disagrees with the cure amount listed in the schedule.40
The Court noted, however, that other courts had taken issue with that line of reasoning. The courts that had insisted on an opt-in mechanism for a third-party release respond to the point above by saying, in substance: “Wait a minute. It is one
[M]any creditors may simply have assumed that a package that related to the Debtors’ bankruptcy case must have related only to their dealings with the Debtors and would not affect their claims against other parties. Charging all inactive creditors with full knowledge of the scope and implications of the proposed third party releases, and implying a ‘consent’ to the third party releases based on the creditors’ inaction, is simply not realistic or fair, and would stretch the meaning of ‘consent’ beyond the breaking point.41
Before Purdue Pharma, this Court believed there was a fair response to that point. At least in this jurisdiction, there was Circuit precedent holding (or, at the very least, strongly implying) that courts could grant nonconsensual third-party releases.42 Whether the provision was appropriate in any particular case would of course depend on the evidence the debtor presented at the confirmation hearing – and the standard was certainly a high one. But in light of the circuit authority, there was nothing that categorically distinguished the third-party release from the schedule of executory contracts and cure amounts. It was a plan provision that might or might not be permissible, based on the evidence to be presented at a later hearing.
But this is what Purdue Pharma changes. After that decision, regardless of what facts the debtor may establish at the confirmation hearing, the third-party release is no longer a potentially permissible plan provision. Accordingly, it is no longer appropriate to require creditors to object or else be subject to (or be deemed to “consent” to) such a third-party release.
Longstanding doctrine in the context of the entry of default judgments in civil litigation under
The rationale of Arsenal, under which the opt-out plan was permitted on the ground that the creditor‘s failure to opt out operated as a default, does not survive Purdue Pharma. Accordingly, such releases cannot be described as “consensual” on the ground that the creditor‘s failure to assert an objection effectively allowed the release to be imposed by virtue of the creditor‘s default. And in the absence of some sort of affirmative expression of consent that would be sufficient as a matter of contract law, the creditor‘s silence in the face of a plan and form of ballot can no longer be sufficient.
The principle that the opt-out plan was justified on the grounds of a creditor‘s default also provided a basis for distinguishing between the “consensual” third-party release before Purdue Pharma and the college education fund plan (described above). The former was the kind of relief that a court could properly enter upon an opposing party‘s default; the latter is not. With that distinction eviscerated, there is no logical limiting principle to what a court might be able to do on the grounds that a creditor threw away the plan and the ballot, and thus “consented” to it. To be sure, a litigant who throws away a validly served legal pleading does so at that litigant‘s risk. That risk, however, is limited to relief that can lawfully be entered against that litigant if
The Purdue Pharma Court‘s discussion of the Bankruptcy Code‘s different treatment of direct versus derivative claims drives home this point. The dissenting opinion had argued that the fact that a debtor may resolve a creditor‘s derivative claims against third parties suggested that the bankruptcy authority was not limited to restructuring the relationship between the debtor and its creditors.47 The majority opinion, however, responded by explaining that the whole point of a claim being derivative is that the claim is not the creditor‘s claim. Rather, the claim is property of the estate, and is thus the debtor‘s to settle or not settle.48 The third-party release, however, “is nothing like that.”49 Rather than being a claim that belongs to the debtor, the third-party release “seeks to extinguish claims against the [third parties] that belong to [the creditors].”50
That point is strikingly similar to the one made by Judge Wiles in Chassix. It is reasonable to require creditors to pay attention to what the debtor is doing in bankruptcy as it relates to the creditor‘s rights against the debtor. But as to the creditor‘s rights against third parties – which belong to the creditor and not the
Accordingly, whatever one might think about the propriety of third-party releases in the world before Purdue Pharma, this Court concludes that in light of that decision, there is no longer a basis to argue with the conclusion in cases like Washington Mutual, Emerge Energy, SunEdison, or Chassix. While the undersigned had previously been comfortable, for the reasons described in Arsenal, concluding that creditors that failed to opt out may be deemed to consent to a plan‘s third-party release, the Court no longer believes it is appropriate to do so.
B. Decisions addressing the issue since Purdue Pharma reinforce this conclusion.
A number of thoughtful bankruptcy court decisions, issued since Purdue Pharma, have addressed this question. In Bowflex, Judge Altenberg emphasized the same due process principles on which this Court relied in Arsenal. In finding that a
None of these cases, however, articulates a limiting principle. This Court does not believe that the courts in Bowflex, Robertshaw, or Invitae would have confirmed a plan that required creditors to donate to the college education fund. The reasoning of those cases, however, suggests no principle that would distinguish the “consensual” third-party releases they approved from a plan provision requiring such a
The part of the analysis that these decisions omit is that the obligation of a party served with pleadings to appear and protect its rights is limited to those circumstances in which it would be appropriate for a court to enter a default judgment if a litigant failed to do so. As described above, that is no longer the case in the context of a third-party release.
The Court finds the reasoning of the bankruptcy court in In re Ebix to be more persuasive.55 That court noted that bankruptcy courts regularly grant relief that is sought in a motion or under a plan when it is unopposed (consider the omnibus claims objection or schedule of cure amounts). The Ebix court pointed out that “in those examples, there is consistently a basis in either the Bankruptcy Code or the Federal Rules of Bankruptcy Procedure or other substantive law contemplating and authorizing that relief.”56 Because there is no such authority to impose a third-party release, the Ebix court found that such releases were only appropriate in circumstances in which, following a contract model, there was evidence of an agreement to grant the release.57 This Court is persuaded by that reasoning. That leaves only the task of applying these principles to the present case.
Under the plan at issue here, priority creditors are to be paid in full and are thus deemed to accept the plan. And the debtors’ equity holders were unimpaired, and also presumed to accept. As such, those parties were not solicited to vote on the plan and were never given an opportunity to opt out. It is true that these parties were informed that the plan would operate to release their claims against third parties. So, under the reasoning of Arsenal, this Court would have found that it was incumbent on those parties to raise an objection if they did not in fact consent to the granting of the third-party release. For the reasons described above, however, that rationale does not survive Purdue Pharma. And as a matter of ordinary contract law, those parties’ silence, in the face of language in the plan telling them that they would be giving the third-party release, is insufficient to bind them to it.
“It is certain that, if the only facts are that A makes an offer to B, and B remains
It bears note, however, that Purdue Pharma also left open the possibility that a nonconsensual third-party release might be appropriate in a “paid-in-full plan.” The Court did not elaborate on what it meant by that. At some level, there may be a common sense to the notion that creditors who have suffered a single, indivisible injury, caused jointly by the debtor and non-debtors, and whose claims on account of that injury have been satisfied in full out of the bankruptcy estate, ought not be permitted to assert those same claims against non-debtors. No party, however, has suggested that this is a basis on which the releases in this case may be justified. The Court therefore does not believe this is an appropriate case to explore the contours of this paid-in-full doctrine, assuming (without deciding) that such a doctrine is even a thing.
The Court finds that regardless of how class 2 creditors voted on the Plan, the vote is an affirmative step, and coupled with conspicuous notice of the opt-out mechanism, suffices as consent to the third-party releases under general contract principles. As to those creditors in class 2 who voted in favor of the plan and elected not to opt out, the Court is satisfied that the plan releases are valid and appropriate as a matter of ordinary contract law. Creditors who returned their ballots and voted in favor of the plan after being informed that doing so, unless they checked the box to opt out, have not been silent. They have taken an affirmative step. And under ordinary contract principles, what they have done is sufficient to hold them to the terms of the release.
In this respect, these creditors are in a position analogous to that of a consumer that makes a purchase over the internet, and “clicks through” to accept the terms and conditions of the sale. The Ninth Circuit explained that such action is typically sufficient to give rise to an enforceable agreement. An “enforceable contract will be found based on an inquiry notice theory only if: (1) the website provides reasonably conspicuous notice of the terms to which the consumer will be bound; and (2) the consumer takes some action, such as clicking a button or checking a box, that unambiguously manifests his or her assent to those terms.”60
The same rationale applies to those creditors in class 2 who voted against the plan and elected not to opt out. They were provided clear instruction that a vote against the Plan would suffice to manifest agreement to a third-party release if they did not affirmatively opt-out by marking the box on the ballot.62 A vote against the plan serves as evidence that the creditor was on notice and actively engaged, and thus has taken an affirmative step such that consent can be established to bind the party to the terms of the release.
The Court appreciates Judge Wiles’ position in Chassix, that “it [is] difficult to understand why any other action should be required to show that the creditor [who voted to reject the plan] also objected to the proposed third party releases… The additional ‘opt out’ requirement, in the context of this case, would have been little
E. The Court need not address here whether a different outcome would be appropriate in a case in which the plan process built in the protections of Rule 23.
The Court also seeks to emphasize a further issue that today‘s decision does not decide. In a recent article, two leading practitioners suggest that in the mass tort context, particularly in a case in which there is a factual basis for a court to make findings akin to those that a court makes when it certifies a
* * *
As noted above, the Court is sympathetic to the argument that a different outcome might better serve the underlying purposes of bankruptcy law, particularly the objectives of encouraging the fair resolution of parties’ disputes in a way that grants all parties a measure of finality. But this Court‘s application of ordinary and settled legal principles leads it to conclude that there is no longer a legal basis to distinguish a traditional opt-out plan from the college education fund plan, which no bankruptcy court would confirm.
That said, this should hardly pose an insurmountable barrier to the successful reorganization of most troubled businesses and their ability to obtain a measure of finality through the bankruptcy process. Nothing in Purdue Pharma can be read to call into question the kind of exculpation approved by the Third Circuit in In re PWS.66 Nor is there a reason why, under Emoral, a debtor may not reach an appropriate resolution of an estate cause of action and thereby relieve third parties
Conclusion
The parties are directed to settle an appropriate order reflecting the foregoing ruling.
Dated: September 25, 2024
CRAIG T. GOLDBLATT
UNITED STATES BANKRUPTCY JUDGE
Language in Confirmation Notice Apprising Creditors of Plan‘s Third-Party Release
On the Effective Date, except as otherwise provided herein and except for the right to enforce this Plan, all persons (i) who voted to accept this Plan or who are presumed to have voted to accept this Plan and (ii) who voted to reject this Plan but did not affirmatively mark the box on the ballot to opt out of granting the releases provided under this Plan, under
section 1126(f) of the Bankruptcy Code shall, to the fullest extent permitted by applicable law, be deemed to forever release, and waive the Released Parties of and from all liens, claims, causes of action, liabilities, encumbrances, security interests, interests or charges of any nature or description whatsoever based or relating to, or in any manner arising from, in whole or in part, the Chapter 11 Case or affecting property of the Estate, whether known or unknown, suspected or unsuspected, scheduled or unscheduled, contingent or not contingent, unliquidated or fixed, admitted or disputed, matured or unmatured, senior or subordinated, whether assertable directly or derivatively by, through, or related to any of the Released Parties and their successors and assigns whether at law, in equity or otherwise, based upon any condition, event, act, omission occurrence, transaction or other activity, inactivity, instrument or other agreement of any kind or nature occurring, arising or existing prior to the Effective Date in any way relating to or arising out of, in whole or in part, the Debtor, the Debtor‘s prepetition operations, governance, financing, or fundraising, the purchase or sale of the Debtor‘s securities, the Chapter 11 Case, the pursuit of Confirmation of this Plan, the consummation of this Plan or the administration of this Plan, including without limitation, the negotiation and solicitation of this Plan, the DIP Loan, and the DIP Loan Documents, all regardless of whether (a) a Proof of Claim or Equity Interest has been filed or is deemed to have been filed, (b) such Claim or Equity Interest is allowed, or (c) the Holder of such Claim or Equity Interest has voted to accept or reject this Plan, except for willful misconduct, gross negligence, fraud or criminal misconduct; provided, however, that the Debtor shall not be a Released Party until the Last Distribution Date if the Plan is confirmed undersection 1191(b) of the Bankruptcy Code. Nothing contained herein shall impact the right of any Holder of an Allowed Claim or interest to receive a Distribution on account of its Allowed Claim or Allowed Interest in accordance with this Plan.
Notes
Another point in Robertshaw warrants mention. The decision in that case emphasized that under